Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology

Launched by UNIVERSITY HOSPITAL, TOULOUSE · May 20, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to screen women who are at high risk of developing cervical cancer due to a long-lasting infection with high-risk types of human papillomavirus (HPV). The goal is to see if it's possible to collect samples from different areas of the body, including the throat and anal regions, to better understand how these infections might lead to cancer. By using advanced testing methods, researchers hope to improve early detection and personalized care for these patients.

To participate in the study, women aged 65 to 74 who have been diagnosed with a persistent high-risk HPV infection or have had previous severe cervical issues, like high-grade lesions or cancer, may be eligible. Participants will need to provide written consent and be covered by a social security plan. If you join the trial, you can expect to be part of a process that aims to improve cancer screening methods while contributing to important research that could benefit many women in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • -Chronic infected patients defined by: Patients with persistent HPV-HR cytological infection (high risk) (as early as 6 months post-treatment of a cervical or vaginal injury), or a recurrence of a high-grade squamous intraepithelial lesion (CIN2 or CIN3 or HSIL) or a recurrence of cancer in the cervix or vagina
• • Patients who have given their written consent to participate in the study.
• • Person affiliated or beneficiary of a social security scheme.
• Exclusion Criteria:
• • Patient with an infection or a persistent lesion after treatment or not, linked only to low-risk HPV.